Bio/Pharma CapEx Trends 2016
List Price: US $997
Delivery format: Electronic PDF delivery within one business day upon payment.
*This report is included at no extra cost for Strategic Advantage clients, and is accessible in the Trend Reports and Analyses section here.
Captive capacity remains the largest impediment to faster growth of the contract manufacturing and development industry. Based on recent capital expenditure trends, it’s clear that bio/pharma companies would rather “make than buy.”
According to the latest PharmSource Trend Report, Bio/Pharma CapEx Trends 2016, bio/pharma companies have invested over $150 billion for new plant and equipment in the past 5 years, an amount at least 10 times greater than what CMOs have invested in themselves. Global and generic bio/pharma companies, in particular, have invested heavily in new capacity, especially for biopharmaceuticals and in emerging markets.
Bio/Pharma CapEx Trends 2016 analyzes recent trends in capital spending by bio/pharma companies and assesses the implications for the CMO industry. It tracks spending by major segments of the bio/pharma industry, with detailed information on investments by global and generic biopharma companies. It discusses the outlook for the next five years, analyzes why major bio/pharma companies continue to favor captive capacity and describes the continuing role of CMOs in the bio/pharma supply chain.
Who should buy this report?
The 16-page report provides important insight that you won’t find in any other source. This report is required reading for:
- CMO executives and strategic decision-makers who seriously follow the global CMO industry, including dose and API manufacturers.
- Bio/Pharma sponsors that buy contract manufacturing services and need to understand contract manufacturing industry drivers.
Published September 2016